Research use only · Lyophilised material · Not a medicine · Not for human or veterinary use · Disclaimer

Comparison · not a ranking

Cagrilintide compared with Retatrutide

Cagrilintide and Retatrutide are separate catalogue items. They are not interchangeable.A CoA for every lot; each vial carries a printed lot number that matches it. Request yours and we email it within 2 hours. Research use only. Not a medicine.

Last verified 9 Nov 2026. UK prices checked daily.

Cagrilintide and Retatrutide are not the same material. Cagrilintide is a peptide (lipidated), while Retatrutide is a 39-residue peptide (lipidated). Cagrilintide: C194H312N54O59S2, 4409.0 g/mol, CAS 1415456-99-3. Retatrutide has no sourced formula or molecular weight on its reference record yet. Each has its own reference record, which lists the source for every figure above. Sable Peptides, a UK supplier operating since 2019, lists both as lyophilised research material; every vial carries a lot number and a certificate of analysis exists for every lot — request yours at /coa-request and we email it within 2 hours. This intro compares identity only and ranks neither compound. Research use only. Not a medicine. Not for human or veterinary use.

Sources: pubchem.ncbi.nlm.nih.gov · pubchem.ncbi.nlm.nih.gov

/ref/cagrilintide · /ref/retatrutide

Cagrilintide and Retatrutide are two records in the Sable Peptides catalogue at https://www.sablepeptides.co.uk/versus/cagrilintide/retatrutide. These prices are both Sable catalogue prices. They are not a comparison with another shop. This page does not rank either compound. Each page shows the catalogue price. A market comparison appears only when an exact, current, approved listing for that size is on record. Only a row with the same amount is a like-for-like price.

Research use only. Not a medicine. Not for human or veterinary use. Disclaimer

Same amount, both catalogue prices. Not a comparison with another seller.
AmountCagrilintideRetatrutide
5 mg£28.00£23.99
10 mg£39.00£23.50

Reference facts

FactCagrilintideRetatrutide
Molecular weight4409.0 g/mol–
Molecular formulaC194H312N54O59S2–
CAS number1415456-99-3–
Compound classpeptide (lipidated)peptide (lipidated)

Sources: pubchem.ncbi.nlm.nih.gov, pubchem.ncbi.nlm.nih.gov Verified 2026-11-09

Category
CagrilintideAnalogues
RetatrutideAnalogues
Research use only
CagrilintideYes
RetatrutideYes
Vials
Cagrilintide3
Retatrutide8
Record
Cagrilintidecagrilintide
Retatrutideretatrutide

Cagrilintide · Retatrutide

Questions this page answers

How does Cagrilintide compare with Retatrutide?
Same vial amounts are shown side by side with each catalogue price. Different amounts are not treated as the same price. No effect is compared, and another seller is not compared.
Which is better?
This page does not say. It does not rank safety, strength, or effect.
What is the lowest catalogue price per mg for Cagrilintide and Retatrutide?
Cagrilintide: £3.90/mg on the 10 mg vial (£39.00). Retatrutide: £1.48/mg on the 40 mg vial (£59.00). Different compounds; this is a catalogue price fact, not a ranking.
How many vial sizes are listed for each?
Cagrilintide: 2 mg, 5 mg, 10 mg. Retatrutide: 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg.

Both compounds

Related research

In-depth comparison

Sable research note. Updated 2026-10-10. Research use only.

Short answer

Cagrilintide and Retatrutide are different compounds. Cagrilintide is an acylated amylin analogue; Retatrutide is an incretin-family peptide (GIP/GLP-1/glucagon receptor triple agonist). Only one of the two has a PubChem compound record, so a direct mass ratio is not given. Sable lists both as freeze-dried research material. Research use only: neither is sold as a medicine, and neither is for use in people or animals.

At a glance

Cagrilintide Retatrutide
Class acylated amylin analogue incretin-family peptide (GIP/GLP-1/glucagon receptor triple agonist)
Formula (PubChem) C194H312N54O59S2 no PubChem record
Molecular weight (PubChem, g/mol) 4409 not listed
PubChem CID 171397054 none found
Sable form freeze-dried powder freeze-dried powder

Structure

Cagrilintide is a long-acting amylin analogue with a disulfide bridge and an N-terminal C20 fatty diacid (19-carboxynonadecanoyl) attached through a gamma-glutamyl linker. PubChem CID 171397054 lists the formula C194H312N54O59S2 and a computed molecular weight of 4409 g/mol (https://pubchem.ncbi.nlm.nih.gov/compound/171397054).

Retatrutide is a 39-residue peptide (development code LY3437943) built on a modified GIP backbone, with Aib at positions 2 and 20, alpha-methyl-leucine at 13, a C-terminal amide, and a C20 fatty diacid attached to Lys17 through a gamma-Glu/AEEA linker. PubChem holds no compound record for Retatrutide under its common names at the time of writing, so no PubChem molecular weight is quoted here. Use the supplier's batch documentation for the expected mass.

Both are peptides, so the meaningful structural differences are sequence, length and modifications rather than chemical category. Differences in residue count, terminal capping (acetylation or amidation), non-natural amino acids and lipid side chains all change molecular weight, solubility and how a compound behaves in an assay. Matching like with like at the structural level is the first step before any comparison of experimental results.

Molecular weight in context

Molecular weight matters in practice for three reasons. First, one milligram of a lighter compound contains more molecules than one milligram of a heavier one, so equal milligram amounts are not equal molar amounts. Second, the expected mass is what identity testing checks against: mass spectrometry on a certificate of analysis should report a value consistent with the formula. Third, salt forms (for example acetate or TFA counter-ions) and metal complexes add mass that a free-base figure does not show, so a certificate may legitimately quote a slightly different value from a database entry.

Class and research context

Cagrilintide: described in the literature as a long-acting amylin- and calcitonin-receptor agonist; an investigational substance.

Retatrutide: described in published trials as an agonist at the GIP, GLP-1 and glucagon receptors; it is an investigational substance, not a licensed medicine and not sold as one.

These descriptions summarise how each compound is characterised in the published literature and in chemical databases. They are not claims about effects in people, and Sable gives no administration or medical-use information for either compound. Readers who need mechanism detail should go to the primary sources and the PubChem literature sections linked below.

How to compare them fairly

  • Compare identity first: formula, sequence and expected mass, then purity.
  • Compare amounts only at the same milligram size, remembering that equal milligrams are not equal moles.
  • Ask for the certificate of analysis for the specific batch. At Sable, every vial is released at ≥99% purity by HPLC with identity checked against the expected mass, and certificates are available for every lot.
  • Treat a search pairing as a navigation habit, not as evidence that two compounds do the same thing.

Sable listings

Vial sizes as listed on 2026-10-10. Each product page carries the current catalogue details.

Cagrilintide (compound guide: https://www.sablepeptides.co.uk/cagrilintide-uk): - Cagrilintide 2 mg: https://www.sablepeptides.co.uk/product/cagrilintide-2mg - Cagrilintide 5 mg: https://www.sablepeptides.co.uk/product/cagrilintide-5mg - Cagrilintide 10 mg: https://www.sablepeptides.co.uk/product/cagrilintide-10mg

Retatrutide (compound guide: https://www.sablepeptides.co.uk/retatrutide-uk): - Retatrutide 5 mg: https://www.sablepeptides.co.uk/product/retatrutide-5mg - Retatrutide 10 mg: https://www.sablepeptides.co.uk/product/retatrutide-10mg - Retatrutide 15 mg: https://www.sablepeptides.co.uk/product/retatrutide-15mg - Retatrutide 20 mg: https://www.sablepeptides.co.uk/product/retatrutide-20mg - Retatrutide 30 mg: https://www.sablepeptides.co.uk/product/retatrutide-30mg - Retatrutide 40 mg: https://www.sablepeptides.co.uk/product/retatrutide-40mg - Retatrutide 50 mg: https://www.sablepeptides.co.uk/product/retatrutide-50mg - Retatrutide 60 mg: https://www.sablepeptides.co.uk/product/retatrutide-60mg

Peptide vials contain freeze-dried powder only; bacteriostatic water is listed separately. Research use only. Not a medicine. Not for human or veterinary use.

Sources

  • PubChem, Cagrilintide: https://pubchem.ncbi.nlm.nih.gov/compound/171397054
  • PubChem search, Retatrutide: https://pubchem.ncbi.nlm.nih.gov/#query=Retatrutide
  • Sable price index and methodology: https://www.sablepeptides.co.uk/pricing/methodology
  • Sable quality and certificate requests: https://www.sablepeptides.co.uk/quality

Comparison questions

What is the difference between Cagrilintide and Retatrutide?

Cagrilintide and Retatrutide are different compounds. Cagrilintide is an acylated amylin analogue; Retatrutide is an incretin-family peptide (GIP/GLP-1/glucagon receptor triple agonist). Only one of the two has a PubChem compound record, so a direct mass ratio is not given. Sable lists both as freeze-dried research material. Research use only: neither is sold as a medicine, and neither is for use in people or animals.

What are the molecular weights of Cagrilintide and Retatrutide?

Cagrilintide: 4409 g/mol (PubChem CID 171397054); Retatrutide: no PubChem record.

Are these sold for use in people?

No. Both are laboratory research material only: not medicines, and not for use in people or animals. No administration or medical-use information is provided.

Cagrilintide and Retatrutide are different research compounds, compared here by vial sizes, price per mg and published identifiers. Sable Peptides sells Cagrilintide from £25.99 and Retatrutide from £23.50. Every lot has an HPLC and mass-spectrometry Certificate of Analysis, emailed within 2 hours of a request.

Updated